The PSMAddition trial shows 177Lu PSMA-617 significantly delays progression in mHSPC when added to hormone therapy, with a ...

Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified interim analysis of Pluvicto.

Novartis (NYSE:NVS) announced positive topline results from the Phase III PSMAddition trial, which showed that its targeted ...

Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive mHSPC: Basel Tuesday, June 3, 2025, 12:00 Hrs [IST] ...

In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3. Almost all mHSPC patients ultimately progress to metastatic ...

Investing.com -- Novartis (SIX: NOVN) on Monday said that its cancer drug Pluvicto showed positive results in a late-stage ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus ...